AG
EPZM

Aperio Group’s Epizyme, Inc EPZM Stock Holding History

Aperio Group’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$164K Buy
+15,083
New +$186K ﹤0.01% 2337
2019
Q3 		– Sell
-5,774
Closed -$72K – 2898
2019
Q2 		$72K Buy
+5,774
New +$74.3K ﹤0.01% 2472

Other funds holding EPZM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KXA
KPCB XIII Associates Menlo Park, California $186M AUM 11.23% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Aperio Group's EPZM Position: Q4 2020 in Review

Aperio Group opened a new position in Epizyme, Inc (EPZM) in Q4 2020: 15,083 shares worth $164K. The stake represents ﹤0.01% of the portfolio and ranks #2337 among its holdings. This is a return to the name: Aperio Group previously reported a position in EPZM as recently as Q2 2019.

Aperio Group first reported a position in EPZM in Q2 2019 and has held it in 2 quarters since. 137 funds tracked by Wall St. Rank hold EPZM as of Q4 2020.

  • Aperio Group held 15,083 shares of Epizyme, Inc worth $164K as of Q4 2020.
  • Epizyme, Inc was a new Aperio Group position in Q4 2020.
  • Epizyme, Inc made up ﹤0.01% of Aperio Group's portfolio in Q4 2020, its #2337 holding.
  • Aperio Group first reported a position in Epizyme, Inc in Q2 2019 and has held it in 2 quarters since.
  • 137 funds tracked by Wall St. Rank held Epizyme, Inc as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.